Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349557 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
A Phase 2 study, sponsored by Benaroya Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00349557 is a Phase 2 study that has completed, run by Benaroya Research Institute. The registered enrollment target is 18 participants.
The verdict
NCT00349557, a Phase 2 study, has completed, sponsored by Benaroya Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the acute and late toxicities from radiation therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks for 12 weeks), bicalutamide (every day for 16 weeks) and goserelin (every 3 months for 2 years).
Interventions
- DRUG bevacizumab, bicalutamide and goserelin
- PROCEDURE intensity modulated radiation therapy (IMRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00349557
The ClinicalTrials.gov registry entry for NCT00349557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Benaroya Research Institute, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab, bicalutamide and goserelin is the first listed.
NCT00349557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00349557 about?
NCT00349557 is a clinical study titled "Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer". The purpose of this study is to determine the acute and late toxicities from radiation therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks for 12 weeks), bicalutamide (every day for 16 weeks) and goserelin (every 3 months for 2 years).
What is the current status of trial NCT00349557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2006-04.
What interventions are being tested in trial NCT00349557?
The interventions under investigation include: bevacizumab, bicalutamide and goserelin (DRUG), intensity modulated radiation therapy (IMRT) (PROCEDURE).
Who is sponsoring clinical trial NCT00349557?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.